Claims
- 1. A method of regressing or reducing the size of a tumor in a subject in need thereof, comprising administering a therapeutically effective amount of an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof wherein the tumor is regressed.
- 2. The method of claim 1, wherein the agent capable of blocking, inhibiting, or ameliorating VEGF-mediated activity is a molecule capable of inhibiting VEGF activity or expression.
- 3. The method of claim 2, wherein the molecule capable of inhibiting VEGF activity or expression is selected from the group consisting of an antibody, a nucleic acid, a VEGF trap, a small molecule, a lipid, and a carbohydrate.
- 4. The method of claim 3, wherein the VEGF trap selected from the group consisting of acetylated Flt-1(1-3)-Fc, Flt-1(1-3R->N)-Fc, Flt-1(1-3ΔB)-Fc, Flt-1(2-3ΔB)-Fc, Flt-1(2-3)-Fc, Flt-1D2-VEGFR3D3-FcΔC1(a), Flt-1D2-Flk-1D3-FcΔC1(a), and VEGFR1R2-FcΔC1(a).
- 5. The method of claim 4, wherein the VEGF trap is VEGFR1R2-FcΔC1(a).
- 6. The method of claim 2, wherein the nucleic acid is an aptamer, an siRNA, or an antisense molecule.
- 7. The method of claim 1, wherein the subject to be treated is a human subject having one or more tumors.
- 8. The method of claim 1, further comprising administering a second agent.
- 9. The method of claim 1, wherein administration is via subcutaneous, intramuscular, intradermal, intraperitoneal, intravenous, intranasal, or oral routes of administration.
- 10. A method of regressing or reducing metastasses in a subject in need thereof, comprising administering a therapeutically effective amount of an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof wherein metastases are regressed or inhibited.
- 11. A method of treating a tumor such that the tumor is reduced in size in a subject in need thereof, comprising administering a therapeutically effective amount of an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof wherein the tumor is treated.
- 12. A method of treating or inhibiting metastatic cancer in a subject in need thereof, comprising administering a therapeutically effective amount of an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof wherein the metastatic cancer is inhibited.
- 13. The method of claim 12, wherein the agent capable of blocking, inhibiting, or ameliorating VEGF-mediated activity is a molecule capable of inhibiting VEGF activity or expression.
- 14. The method of claim 13, wherein the molecule capable of inhibiting VEGF activity or expression is selected from the group consisting of an antibody, a nucleic acid, a VEGF trap, a small molecule, a lipid, and a carbohydrate.
- 15. The method of claim 14, wherein the VEGF trap selected from the group consisting of acetylated Flt-1(1-3)-Fc, Flt-1(1-3R->N)-Fc, Flt-1(1-3ΔB)-Fc, Flt-1(2-3ΔB)-Fc, Flt-1(2-3)-Fc, Flt-1D2-VEGFR3D3-FcΔC1(a), Flt-1D2-Flk-1D3-FcΔC1(a), and VEGFR1R2-FcΔC1(a).
- 16. The method of claim 14, wherein the VEGF trap is VEGFR1R2-FcΔC1(a).
- 17. The method of claim 14, wherein the nucleic acid is an aptamer, an siRNA, or an antisense molecule.
- 18. The method of claim 1, further comprising administering a second agent.
- 19. An article of manufacturing, comprising:
(a) packaging material; and (b) a pharmaceutical agent contained within the packaging material, wherein the pharmaceutical agent comprises at least agent capable of inhibiting vascular endothelial growth factor (VEGF), and wherein the packaging material comprises a label or packaging insert which indicates that the agent can be used for tumor regression.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 USC § 119(e) of U.S. Provisional 60/476,425 filed 6 Jun. 2003, which application is herein specifically incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60476425 |
Jun 2003 |
US |